| P2093 | author name string | D H Lee | |
| | M J Lee | |
| | Y K Kim | |
| | K Kim | |
| | T H Kim | |
| | J-Y Jeong | |
| | H J An | |
| | Y J Jung | |
| | J H Huh | |
| | J-A Song | |
| P2860 | cites work | A microRNA expression signature of human solid tumors defines cancer gene targets | Q24541455 |
| | The functions of animal microRNAs | Q27860621 |
| | Oncomirs - microRNAs with a role in cancer | Q27860773 |
| | Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets | Q27860792 |
| | MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 |
| | miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells | Q28278471 |
| | Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia | Q28306681 |
| | Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines | Q28975767 |
| | miR-21-mediated tumor growth | Q29616149 |
| | MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN | Q29616575 |
| | A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma | Q34178892 |
| | Cancer of the ovary | Q34375262 |
| | A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship | Q34690734 |
| | miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy | Q34996775 |
| | ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells. | Q36235795 |
| | MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression | Q36498054 |
| | Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study | Q36912591 |
| | The role of the ZEB family of transcription factors in development and disease. | Q37326462 |
| | Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer | Q37725034 |
| | Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-beta1-mediated growth suppression in adult T-cell leukemia/lymphoma | Q39698194 |
| | Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells | Q39706295 |
| | MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy | Q39880558 |
| | Role of microRNAs in drug-resistant ovarian cancer cells | Q39934697 |
| | MicroRNAs modulate the chemosensitivity of tumor cells | Q40026480 |
| | Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype | Q40076490 |
| | Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors | Q41376475 |
| | MicroRNA expression profiles in serous ovarian carcinoma. | Q53321694 |
| | Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer | Q57202934 |
| | Analysis of BCL-10 gene mutations in ovarian cancer cell lines | Q73245508 |
| | MicroRNAs in cell proliferation, cell death, and tumorigenesis | Q80060447 |
| | Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients | Q83840777 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| | paclitaxel | Q423762 |
| P304 | page(s) | 452-461 | |
| P577 | publication date | 2013-06-27 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer | |
| P478 | volume | 109 | |